congresses-banner

The content contained is subject

PublicationView

Poster
T-DXd, Valemetostat
ESMO GI 2024 | June 26 – 29, 2024
Gastric Cancer
Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated, advanced, or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma
Kohei Shitara

footer